Search all trials

Find therapies in clinical trials near you – page 17

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 968
countries: 28
conditions: 2 103

3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Durvalumab and Olaparib for Patients with Stage IV Non-Small Cell Lung Cancer After Initial Chemotherapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on the Safety and Effects of PDC*lung01 Vaccine with Pemetrexed or Pembrolizumab for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Erlotinib and LY2875358 for Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations After Initial Erlotinib Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Emibetuzumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab, Pemetrexed, and Carboplatin for Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Registered drugNo placebo

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Lithuania

Participants:18–64 years · 65+ years
Substances:Osimertinib

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Bevacizumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

Registered drug

Hungary

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Registered drugNo placebo

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Methotrexate, Dexamethasone, and Montelukast to Prevent Infusion Reactions in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dexamethasone

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Find therapies in clinical trials near you – page 17

327 trials match your criteria

Non-small cell lung cancer

Study on the Effectiveness and Safety of Durvalumab and Olaparib for Patients with Stage IV Non-Small Cell Lung Cancer After Initial Chemotherapy

Non-small cell lung cancer

Study on the Safety and Effects of PDC*lung01 Vaccine with Pemetrexed or Pembrolizumab for Patients with Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study of Erlotinib and LY2875358 for Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations After Initial Erlotinib Treatment

Non-small cell lung cancer

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study of Pembrolizumab, Pemetrexed, and Carboplatin for Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer+1

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Non-small cell lung cancer

Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

Non-small cell lung cancer+2

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Non-small cell lung cancer

Study on Methotrexate, Dexamethasone, and Montelukast to Prevent Infusion Reactions in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Non-small cell lung cancer

Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

Non-small cell lung cancer

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.